Intersect ENT

Intersect ENT is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The Company markets the first and only drug-releasing sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
Company Growth (employees)
Menlo Park, US
Size (employees)
303 (est)
Intersect ENT was founded in 2003 and is headquartered in Menlo Park, US

Key People at Intersect ENT

Lisa Earnhardt

Lisa Earnhardt

President & CEO
Monika De Martini

Monika De Martini

Robrt Binney

Robrt Binney

Vice President of Sales
Amy Wolbeck

Amy Wolbeck

Vice President, Regulatory Affairs and Quality
Susan P Stimson

Susan P Stimson

Vice President of Marketing
Rich Kaufman

Rich Kaufman

Senior Vice President and Chief Operating Officer

Intersect ENT Office Locations

Intersect ENT has an office in Menlo Park
Menlo Park, US (HQ)
1555 Adams Dr

Intersect ENT Data and Metrics

Intersect ENT Financial Metrics

Intersect ENT's revenue was reported to be $20.5 m in Q1, 2017

Revenue (Q1, 2017)

20.5 m

Gross profit (Q1, 2017)

17.6 m

Gross profit margin (Q1, 2017), %


Net income (Q1, 2017)

(6.7 m)

EBIT (Q1, 2017)

(6.9 m)

Market capitalization (21-Sep-2017)

846.8 m

Cash (31-Dec-2016)

9.9 m
Intersect ENT's current market capitalization is $846.8 m.
USDFY, 2014FY, 2015FY, 2016


38.6 m61.6 m78.7 m

Revenue growth, %


Cost of goods sold

10.2 m12.3 m13 m

Gross profit

28.4 m49.3 m65.7 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


15.2 m14.2 m16.7 m19.3 m18.5 m20.5 m

Cost of goods sold

2.9 m2.9 m3.2 m3.1 m2.8 m2.9 m

Gross profit

12.3 m11.4 m13.5 m16.2 m15.7 m17.6 m

Gross profit Margin, %

USDFY, 2014FY, 2015FY, 2016


13.4 m34.8 m9.9 m

Accounts Receivable

8.3 m11.5 m14.4 m


951 k1.5 m1.3 m

Current Assets

60.3 m141.2 m125.3 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(18.4 m)(26.6 m)(25.2 m)

Depreciation and Amortization

1.2 m

Accounts Receivable

(4.1 m)(3.1 m)(3 m)


(541 k)(544 k)(1.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.8 m)(9.7 m)(8.2 m)(6 m)(6.2 m)(6.7 m)

Accounts Receivable

4.5 m4.9 m8 m8.8 m8.5 m9.5 m10 m10 m12.3 m


2.8 m2.7 m2.8 m3.2 m3.7 m4.9 m5.9 m7.2 m7.1 m

Accounts Payable

2.7 m2.1 m2 m2.5 m3.2 m2.9 m2.6 m3.2 m2.3 m
USDY, 2017


67.6 k
Show all financial metrics

Intersect ENT Operating Metrics

Intersect ENT's Accounts was reported to be 2.4 k in FY, 2016. Intersect ENT's Patients Served was reported to be 150 k in FY, 2016
FY, 2016

Patients Served

150 k

Patents Issued




Trademarks Pending

Show all operating metrics

Intersect ENT Market Value History

Traffic Overview of Intersect ENT

Intersect ENT Online and Social Media Presence

Intersect ENT Company Life and Culture

You may also be interested in